• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞生长因子、白细胞介素-1α和白细胞介素-27是新冠病毒肺炎患者早期严重程度分层的有力生物标志物。

HGF, IL-1α, and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients.

作者信息

Tamayo-Velasco Álvaro, Martínez-Paz Pedro, Peñarrubia-Ponce María Jesús, de la Fuente Ignacio, Pérez-González Sonia, Fernández Itziar, Dueñas Carlos, Gómez-Sánchez Esther, Lorenzo-López Mario, Gómez-Pesquera Estefanía, Heredia-Rodríguez María, Carnicero-Frutos Irene, Muñoz-Moreno María Fe, Bernardo David, Álvarez Francisco Javier, Tamayo Eduardo, Gonzalo-Benito Hugo

机构信息

Department of Hematology, University Clinical Hospital, 47003 Valladolid, Spain.

Department of Surgery, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain.

出版信息

J Clin Med. 2021 May 8;10(9):2017. doi: 10.3390/jcm10092017.

DOI:10.3390/jcm10092017
PMID:34066892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8125923/
Abstract

Pneumonia is the leading cause of hospital admission and mortality in coronavirus disease 2019 (COVID-19). We aimed to identify the cytokines responsible for lung damage and mortality. We prospectively recruited 108 COVID-19 patients between March and April 2020 and divided them into four groups according to the severity of respiratory symptoms. Twenty-eight healthy volunteers were used for normalization of the results. Multiple cytokines showed statistically significant differences between mild and critical patients. High HGF levels were associated with the critical group (OR = 3.51; < 0.001; 95%CI = 1.95-6.33). Moreover, high IL-1α (OR = 1.36; = 0.01; 95%CI = 1.07-1.73) and low IL-27 (OR = 0.58; < 0.005; 95%CI = 0.39-0.85) greatly increased the risk of ending up in the severe group. This model was especially sensitive in order to predict critical status (AUC = 0.794; specificity = 69.74%; sensitivity = 81.25%). Furthermore, high levels of HGF and IL-1α showed significant results in the survival analysis ( = 0.033 and = 0.011, respectively). HGF, IL-1α, and IL 27 at hospital admission were strongly associated with severe/critical COVID-19 patients and therefore are excellent predictors of bad prognosis. HGF and IL-1α were also mortality biomarkers.

摘要

肺炎是2019冠状病毒病(COVID-19)患者住院和死亡的主要原因。我们旨在确定导致肺损伤和死亡的细胞因子。2020年3月至4月,我们前瞻性招募了108例COVID-19患者,并根据呼吸道症状的严重程度将他们分为四组。28名健康志愿者用于结果的标准化。轻度和重症患者之间多种细胞因子存在统计学显著差异。高HGF水平与重症组相关(OR = 3.51;<0.001;95%CI = 1.95 - 6.33)。此外,高IL-1α(OR = 1.36;= 0.01;95%CI = 1.07 - 1.73)和低IL-27(OR = 0.58;<0.005;95%CI = 0.39 - 0.85)大大增加了最终进入重症组的风险。该模型在预测重症状态方面特别敏感(AUC = 0.794;特异性 = 69.74%;敏感性 = 81.25%)。此外,高HGF和IL-1α水平在生存分析中显示出显著结果(分别为 = 0.033和 = 0.011)。入院时的HGF、IL-1α和IL-27与重症/危重症COVID-19患者密切相关,因此是不良预后的优秀预测指标。HGF和IL-1α也是死亡生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb70/8125923/30d5a89729da/jcm-10-02017-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb70/8125923/c1ea0bc6d9fd/jcm-10-02017-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb70/8125923/63dadbe69ae9/jcm-10-02017-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb70/8125923/30d5a89729da/jcm-10-02017-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb70/8125923/c1ea0bc6d9fd/jcm-10-02017-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb70/8125923/63dadbe69ae9/jcm-10-02017-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb70/8125923/30d5a89729da/jcm-10-02017-g003.jpg

相似文献

1
HGF, IL-1α, and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients.肝细胞生长因子、白细胞介素-1α和白细胞介素-27是新冠病毒肺炎患者早期严重程度分层的有力生物标志物。
J Clin Med. 2021 May 8;10(9):2017. doi: 10.3390/jcm10092017.
2
Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.分析 COVID-19 患者的血清细胞因子表明,IL-6 和 IL-10 是疾病严重程度的预测因子。
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130. doi: 10.1080/22221751.2020.1770129.
3
[Comparison of severity classification of Chinese protocol, pneumonia severity index and CURB-65 in risk stratification and prognostic assessment of coronavirus disease 2019].[中国方案、肺炎严重程度指数及CURB-65在2019冠状病毒病风险分层及预后评估中的严重程度分类比较]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Oct 12;43(10):834-838. doi: 10.3760/cma.j.cn112147-20200226-00186.
4
[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].[29例2019新型冠状病毒肺炎患者临床特征分析]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):203-208. doi: 10.3760/cma.j.issn.1001-0939.2020.03.013.
5
[Value of interleukin-6 and CD4 T-lymphocytopenia in assessing the severity and prognosis of coronavirus disease 2019].[白细胞介素-6及CD4 T淋巴细胞减少在评估2019冠状病毒病严重程度及预后中的价值]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Oct;32(10):1165-1170. doi: 10.3760/cma.j.cn121430-20200521-00395.
6
[Relationship between D-dimer concentration and inflammatory factors or organ function in patients with coronavirus disease 2019].2019冠状病毒病患者D-二聚体浓度与炎症因子或器官功能的关系
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 May;32(5):559-563. doi: 10.3760/cma.j.cn121430-20200414-00518.
7
Characterization of the Inflammatory Response to Severe COVID-19 Illness.严重 COVID-19 疾病炎症反应的特征。
Am J Respir Crit Care Med. 2020 Sep 15;202(6):812-821. doi: 10.1164/rccm.202005-1583OC.
8
National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 - a prospective cohort study.入院时的国家早期预警评分 2 (NEWS2)可预测新冠病毒疾病的严重程度和住院死亡率-一项前瞻性队列研究。
Scand J Trauma Resusc Emerg Med. 2020 Jul 13;28(1):66. doi: 10.1186/s13049-020-00764-3.
9
IL-6-based mortality risk model for hospitalized patients with COVID-19.基于 IL-6 的 COVID-19 住院患者死亡风险模型。
J Allergy Clin Immunol. 2020 Oct;146(4):799-807.e9. doi: 10.1016/j.jaci.2020.07.009. Epub 2020 Jul 22.
10
[Analysis of the changes of inflammatory cytokine levels in patients with critical coronavirus disease 2019 undergoing invasive mechanical ventilation].[2019 冠状病毒病危重症患者有创机械通气时炎症细胞因子水平变化分析]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Sep;32(9):1051-1055. doi: 10.3760/cma.j.cn121430-20200414-00519.

引用本文的文献

1
Genetic liability to systemic inflammatory regulators is causally linked to COVID-19 diverse phenotypes: Insights from multi-omics association study and single-cell RNA sequencing analysis.全身炎症调节因子的遗传易感性与新冠病毒病的多种表型存在因果关系:多组学关联研究和单细胞RNA测序分析的见解
Medicine (Baltimore). 2025 Aug 22;104(34):e44089. doi: 10.1097/MD.0000000000044089.
2
Patients Hospitalized with COVID-19 Demonstrate Distinct Plasma Cytokine and Chemokine Concentrations in vivo and TLR-Mediated Cytokine and Chemokine Production in Whole Blood in vitro.感染新冠病毒住院患者体内血浆细胞因子和趋化因子浓度各异,且体外全血中TLR介导的细胞因子和趋化因子产生情况也有所不同。
J Innate Immun. 2025;17(1):288-301. doi: 10.1159/000545432. Epub 2025 May 28.
3

本文引用的文献

1
Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome.可溶性白细胞介素-6 受体在 COVID-19 细胞因子风暴综合征中的作用。
Cell Rep Med. 2021 May 18;2(5):100269. doi: 10.1016/j.xcrm.2021.100269. Epub 2021 Apr 19.
2
Interleukin-6: obstacles to targeting a complex cytokine in critical illness.白细胞介素-6:危重病中靶向一种复杂细胞因子的障碍。
Lancet Respir Med. 2021 Jun;9(6):643-654. doi: 10.1016/S2213-2600(21)00103-X. Epub 2021 Apr 16.
3
COVID-19 and the human innate immune system.新型冠状病毒肺炎与人类固有免疫系统。
Long-term mitochondrial and metabolic impairment in lymphocytes of subjects who recovered after severe COVID-19.重症 COVID-19 康复者淋巴细胞的长期线粒体和代谢损伤
Cell Biol Toxicol. 2025 Jan 10;41(1):27. doi: 10.1007/s10565-024-09976-0.
4
Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study.新冠病毒感染康复后12个月勃起功能障碍风险预测模型的开发:一项前瞻性观察研究。
J Clin Med. 2024 Sep 27;13(19):5757. doi: 10.3390/jcm13195757.
5
Regulation of plasma soluble receptors of TNF and IL-1 in patients with COVID-19 differs from that observed in sepsis.新型冠状病毒肺炎患者血浆中肿瘤坏死因子(TNF)和白细胞介素-1(IL-1)可溶性受体的调节与脓毒症患者不同。
J Infect. 2024 Dec;89(6):106300. doi: 10.1016/j.jinf.2024.106300. Epub 2024 Sep 30.
6
IL-27 expression regulation and its effects on adaptive immunity against viruses.IL-27 的表达调控及其对病毒适应性免疫的影响。
Front Immunol. 2024 Jun 20;15:1395921. doi: 10.3389/fimmu.2024.1395921. eCollection 2024.
7
Effects of Combined Treatment with Sodium Dichloroacetate and Sodium Valproate on the Genes in Inflammation- and Immune-Related Pathways in T Lymphocytes from Patients with SARS-CoV-2 Infection with Pneumonia: Sex-Related Differences.二氯醋酸钠与丙戊酸钠联合治疗对新型冠状病毒肺炎合并感染患者T淋巴细胞炎症和免疫相关通路基因的影响:性别差异
Pharmaceutics. 2024 Mar 16;16(3):409. doi: 10.3390/pharmaceutics16030409.
8
Changes in chemokine and growth factor levels may be useful biomarkers for monitoring disease severity in COVID-19 patients; a pilot study.趋化因子和生长因子水平的变化可能是监测 COVID-19 患者疾病严重程度的有用生物标志物;一项初步研究。
Front Immunol. 2024 Jan 4;14:1320362. doi: 10.3389/fimmu.2023.1320362. eCollection 2023.
9
Severity of oxidative stress as a hallmark in COVID-19 patients.氧化应激的严重程度作为 COVID-19 患者的特征之一。
Eur J Med Res. 2023 Dec 4;28(1):558. doi: 10.1186/s40001-023-01401-2.
10
Clinical severity classes in COVID-19 pneumonia have distinct immunological profiles, facilitating risk stratification by machine learning.COVID-19 肺炎的临床严重程度分类具有不同的免疫学特征,有助于通过机器学习进行风险分层。
Front Immunol. 2023 Sep 5;14:1192765. doi: 10.3389/fimmu.2023.1192765. eCollection 2023.
Cell. 2021 Apr 1;184(7):1671-1692. doi: 10.1016/j.cell.2021.02.029. Epub 2021 Feb 16.
4
IL-6-based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts.基于 IL-6 的 COVID-19 死亡率预测模型:多中心和第二波队列的验证和更新。
J Allergy Clin Immunol. 2021 May;147(5):1652-1661.e1. doi: 10.1016/j.jaci.2021.02.021. Epub 2021 Mar 1.
5
A neutrophil activation signature predicts critical illness and mortality in COVID-19.中性粒细胞激活特征可预测 COVID-19 患者的重症和死亡风险。
Blood Adv. 2021 Mar 9;5(5):1164-1177. doi: 10.1182/bloodadvances.2020003568.
6
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
7
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
8
IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.IL-6 血清水平可预测 COVID-19 的严重程度和对托珠单抗的反应:一项观察性研究。
J Allergy Clin Immunol. 2021 Jan;147(1):72-80.e8. doi: 10.1016/j.jaci.2020.09.018. Epub 2020 Sep 30.
9
Longitudinal analyses reveal immunological misfiring in severe COVID-19.纵向分析揭示了重症 COVID-19 中的免疫失调。
Nature. 2020 Aug;584(7821):463-469. doi: 10.1038/s41586-020-2588-y. Epub 2020 Jul 27.
10
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.